(BSX) Boston Scientific - Ratings and Ratios
Stents, Catheters, Pacemakers, Defibrillators, Lasers
BSX EPS (Earnings per Share)
BSX Revenue
Description: BSX Boston Scientific September 25, 2025
Boston Scientific Corp (NYSE:BSX) designs, manufactures, and markets a broad range of medical devices across two primary segments-MedSurg and Cardiovascular-serving interventional specialties worldwide. The firm, founded in 1979 and based in Marlborough, Massachusetts, leverages a diversified product slate that spans gastrointestinal, urological, neurological, and cardiac therapies.
Within MedSurg, the company offers gastrointestinal tools (e.g., resolution clips, biliary stents, single-use duodenoscopes), urology solutions (ureteral stents, digital flexible ureteroscopes, holmium lasers, penile implants), and neuromodulation technologies (spinal cord stimulators, deep-brain stimulation systems). The Cardiovascular segment includes coronary disease and aortic valve devices, the WATCHMAN FLX left-atrial appendage closure system, and a suite of implantable cardiac rhythm management products such as CRT-D/CRT-P pacemakers, MRI-compatible sub-cutaneous ICDs, and remote monitoring platforms.
Key performance indicators suggest solid momentum: FY 2023 revenue reached roughly $12.6 billion, with MedSurg contributing about 55% and delivering a 23% operating margin, while Cardiovascular posted a 21% margin. R&D intensity remains near 9% of sales, reflecting continued pipeline investment. Sector-wide drivers-an aging U.S. population, rising prevalence of chronic cardiovascular and gastrointestinal conditions, and a projected 5% CAGR in global healthcare spending-support demand growth for BSX’s high-margin devices.
For a deeper, data-driven assessment of Boston Scientific’s valuation and risk profile, you may find ValueRay’s analytical dashboards useful.
BSX Stock Overview
| Market Cap in USD | 146,154m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 1992-05-18 |
BSX Stock Ratings
| Growth Rating | 76.6% |
| Fundamental | 71.3% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -0.18% |
| Analyst Rating | 4.59 of 5 |
BSX Dividends
Currently no dividends paidBSX Growth Ratios
| Growth Correlation 3m | -54.9% |
| Growth Correlation 12m | 43.2% |
| Growth Correlation 5y | 93.8% |
| CAGR 5y | 31.63% |
| CAGR/Max DD 3y (Calmar Ratio) | 2.04 |
| CAGR/Mean DD 3y (Pain Ratio) | 12.02 |
| Sharpe Ratio 12m | 0.47 |
| Alpha | 3.58 |
| Beta | 0.614 |
| Volatility | 20.23% |
| Current Volume | 6810k |
| Average Volume 20d | 7105.5k |
| Stop Loss | 96 (-3.1%) |
| Signal | 0.65 |
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income (2.79b TTM) > 0 and > 6% of Revenue (6% = 1.16b TTM) |
| FCFTA 0.08 (>2.0%) and ΔFCFTA 3.79pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 2.69% (prev 17.92%; Δ -15.23pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.11 (>3.0%) and CFO 4.29b > Net Income 2.79b (YES >=105%, WARN >=100%) |
| Net Debt (10.73b) to EBITDA (4.68b) ratio: 2.29 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.08 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.50b) change vs 12m ago 0.54% (target <= -2.0% for YES) |
| Gross Margin 65.05% (prev 62.41%; Δ 2.64pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 49.95% (prev 41.78%; Δ 8.17pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 6.57 (EBITDA TTM 4.68b / Interest Expense TTM 403.0m) >= 6 (WARN >= 3) |
Altman Z'' 0.95
| (A) 0.01 = (Total Current Assets 6.92b - Total Current Liabilities 6.40b) / Total Assets 39.40b |
| (B) 0.07 = Retained Earnings (Balance) 2.67b / Total Assets 39.40b |
| (C) 0.07 = EBIT TTM 2.65b / Avg Total Assets 38.74b |
| (D) 0.17 = Book Value of Equity 2.96b / Total Liabilities 17.39b |
| Total Rating: 0.95 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 71.32
| 1. Piotroski 7.50pt = 2.50 |
| 2. FCF Yield 2.11% = 1.06 |
| 3. FCF Margin 17.11% = 4.28 |
| 4. Debt/Equity 0.51 = 2.37 |
| 5. Debt/Ebitda 2.29 = -0.57 |
| 6. ROIC - WACC (= -1.33)% = -1.66 |
| 7. RoE 12.80% = 1.07 |
| 8. Rev. Trend 98.97% = 7.42 |
| 9. EPS Trend 97.14% = 4.86 |
What is the price of BSX shares?
Over the past week, the price has changed by -1.51%, over one month by +2.43%, over three months by -3.79% and over the past year by +14.59%.
Is Boston Scientific a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BSX is around 108.28 USD . This means that BSX is currently overvalued and has a potential downside of 9.32%.
Is BSX a buy, sell or hold?
- Strong Buy: 23
- Buy: 8
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the BSX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 126.2 | 27.4% |
| Analysts Target Price | 126.2 | 27.4% |
| ValueRay Target Price | 119.9 | 21.1% |
BSX Fundamental Data Overview November 05, 2025
P/E Trailing = 52.7219
P/E Forward = 28.49
P/S = 7.5536
P/B = 6.3598
P/EG = 1.4736
Beta = 0.614
Revenue TTM = 19.35b USD
EBIT TTM = 2.65b USD
EBITDA TTM = 4.68b USD
Long Term Debt = 8.84b USD (from longTermDebt, last fiscal year)
Short Term Debt = 1.78b USD (from shortTermDebt, last fiscal year)
Debt = 11.15b USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = 10.73b USD (from netDebt column, last fiscal year)
Enterprise Value = 156.89b USD (146.15b + Debt 11.15b - CCE 414.0m)
Interest Coverage Ratio = 6.57 (Ebit TTM 2.65b / Interest Expense TTM 403.0m)
FCF Yield = 2.11% (FCF TTM 3.31b / Enterprise Value 156.89b)
FCF Margin = 17.11% (FCF TTM 3.31b / Revenue TTM 19.35b)
Net Margin = 14.41% (Net Income TTM 2.79b / Revenue TTM 19.35b)
Gross Margin = 65.05% ((Revenue TTM 19.35b - Cost of Revenue TTM 6.76b) / Revenue TTM)
Gross Margin QoQ = 69.93% (prev 67.65%)
Tobins Q-Ratio = 3.98 (Enterprise Value 156.89b / Total Assets 39.40b)
Interest Expense / Debt = 0.78% (Interest Expense 87.0m / Debt 11.15b)
Taxrate = 19.49% (183.0m / 939.0m)
NOPAT = 2.13b (EBIT 2.65b * (1 - 19.49%))
Current Ratio = 1.08 (Total Current Assets 6.92b / Total Current Liabilities 6.40b)
Debt / Equity = 0.51 (Debt 11.15b / totalStockholderEquity, last fiscal year 21.77b)
Debt / EBITDA = 2.29 (Net Debt 10.73b / EBITDA 4.68b)
Debt / FCF = 3.24 (Net Debt 10.73b / FCF TTM 3.31b)
Total Stockholder Equity = 21.78b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.08% (Net Income 2.79b / Total Assets 39.40b)
RoE = 12.80% (Net Income TTM 2.79b / Total Stockholder Equity 21.78b)
RoCE = 8.64% (EBIT 2.65b / Capital Employed (Equity 21.78b + L.T.Debt 8.84b))
RoIC = 6.41% (NOPAT 2.13b / Invested Capital 33.22b)
WACC = 7.74% (E(146.15b)/V(157.30b) * Re(8.28%) + D(11.15b)/V(157.30b) * Rd(0.78%) * (1-Tc(0.19)))
Discount Rate = 8.28% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.63%
[DCF Debug] Terminal Value 80.68% ; FCFE base≈2.69b ; Y1≈3.32b ; Y5≈5.66b
Fair Price DCF = 62.05 (DCF Value 91.98b / Shares Outstanding 1.48b; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 97.14 | EPS CAGR: 16.74% | SUE: 2.12 | # QB: 11
Revenue Correlation: 98.97 | Revenue CAGR: 17.61% | SUE: 2.10 | # QB: 8
Additional Sources for BSX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle